AI can design a molecule in seconds, however someone still has to build it and test it before it means anything.

You're pouring resources into AI-driven molecule design, but nobody on your team has answered the harder question: can you actually make what the model just designed?

Patrick Finn is President and Chief Operating Officer of Twist Bioscience, a company writing DNA on silicon chips at a scale of roughly 32 million distinct oligonucleotides a day. Under his leadership, Twist has become the manufacturing layer behind antibody discovery, liquid biopsy, and molecular residual disease testing programs across biotech.

You'll get a clear picture of what happens after an AI model produces a candidate molecule, and why the synthesis step decides whether that design ever becomes usable data. Paddy breaks down how pooled DNA synthesis and display selection turn hundreds of thousands of candidates into model feedback in weeks instead of months, and where the manufacturability gap bites hardest as AI pushes sequences into territory nature never explored.

This episode covers high-throughput DNA synthesis, target enrichment for liquid biopsy, tumor-informed molecular residual disease testing, and the economics of scaling antibody discovery. It's built for data and R&D leaders investing in AI-driven drug discovery who haven't stress-tested the physical layer underneath their models, plus anyone in biotech data science curious how life sciences data pipelines actually generate their evidence.

Key Takeaways

Twist's silicon chip platform pushes roughly 32 million oligonucleotides through synthesis every day, and that scale is what turns a single AI-designed antibody into a dataset instead of a guess.
Liquid biopsy tests need sequencing depth around 50,000x coverage to catch a signal in the noise, and target enrichment panels can cut total sequencing costs by roughly half.
AI models are pushing sequence designs into territory that's genuinely hard to manufacture: homopolymers, long repeats, extreme GC content. Twist's acceptance rate on submitted sequences climbed from 96% to 99.5%, and that gap matters more than it sounds.
Memorial Sloan Kettering sent Twist 100,000 antibody designs and had the entire set synthesized as a single pooled library, tested through phage or yeast display, instead of one sequence at a time.

Chapter Markers

00:00 Introduction to Twist Bioscience and Paddy Finn

01:12 Overview of Twist's silicon DNA synthesis platform

04:13 How miniaturized chips drive 32 million oligos daily

05:35 Killer applications built on Twist's infrastructure

07:44 Liquid biopsy and the cost of sequencing depth

12:02 How target enrichment lowers diagnostic costs

13:15 Tumor-informed molecular residual disease testing

16:30 What "disease-free" really means in MRD testing

18:02 Producing and characterizing antibodies at scale

22:25 The assay menu behind antibody developability

24:04 Why AI-designed sequences are hard to manufacture

27:36 Predicting manufacturability before synthesis begins

31:16 Going from 96% to 99.5% sequence acceptance

33:16 Wet lab partnership with Amazon and Memorial Sloan Kettering

36:10 Why Twist stays an enabler, not a model builder

38:20 Is AI-driven biology durable, or a short cycle

41:53 What R&D leaders should ask before scaling AI design

43:00 Ross's takeaways: bottlenecks move, they don't disappear

Useful Links & Resources

Twist Bioscience: https://www.twistbioscience.com
Patrick Finn on LinkedIn: https://www.linkedin.com/in/patrickjfinn/
CorrDyn: https://www.corrdyn.com
Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/

#DataInBiotech #BiotechDataScience #DrugDiscovery #LifeSciences #AIinBiotech

The Charm Offensive That Isn't

Face-Off

Soft Power Version 2.0: Tech-Driven Influence

The AI-powered Podcast Player